colorectal cancer (Stage3, 4)
Conditions
Interventions
Patients of stage 3a recieved UFT+l-LV( day1-28) and autologous tumor lysate-pulsed dendritic cells (day8,22) every 2 weeks.This treatment repeats 6 courses, or recieved capecitabine (day1-14) and au
Sponsors
Tomishiro Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Colorectal cancer patients who are histopathologically diagnosed as Stage3b or 4 and adenocarcinoma; (1)Tumor tissue is preserved after resection and tumor lysate is aseptically prepared; (2)No serious abnormality in heart, lung, bone marrow, liver, and renal functions; (3)Performance Status is 0-1; (4)Apheresis is feasibile.
Exclusion criteria
Exclusion criteria: Patients who have: (1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them (2)Serious drug allergy (3)Serious cardiac disease (4)Active autoimmune disease (5)Other cancers (6)Drainage is necessary (pleural/ascites effusion ) (7)Brain metastasis with symptoms (8)Edema which needs treatment (9)Positive for HIV or HTLV-1 (10)Continuous systematic administration of steroids within 4 weeks (20mg or more on a predonine conversion basis) (11)Uncontrollable infection (12)Pregnant or lactating (13)Gelling of plasma, cryoglobulinemia (14)Any reason why, in the opinion of the investigator, the patient should not participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological responses Antitumor effect progression-free survival event-free survival overall survival | — |
Countries
Japan
Contacts
Public ContactAtsushi Ochiai
Tomishiro Central Hospital Office of Clinical Trial
Outcome results
None listed